Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Acadia Pharma (ACAD) Tops Q1 EPS by 11c
May 5, 2021 4:35 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.42), $0.11 better than the analyst estimate of ($0.53). Revenue for the quarter came in at $106.6 million versus the consensus estimate of $111.63 million.
Reiterating FY21 net sales guidance of $510 to $550 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More